Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - mesalazine 800mg - enteric coated tablet - 800 mg - active: mesalazine 800mg excipient: iron oxide red iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate methacrylic acid copolymer povidone purified talc   sodium starch glycolate triethyl citrate - ulcerative colitis: induction of remission of mild to moderate episodes. maintenance of remission.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - mesalazine 16.67%{relative} - suppository - 16.67% w/w - active: mesalazine 16.67%{relative} excipient: hard fat

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - budesonide 3mg - modified release capsule - 3 mg - active: budesonide 3mg excipient: acetyl tributyl citrate ethylcellulose gelatin methacrylic acid - ethyl acrylate copolymer polysorbate 80 purified talc simeticone sugar spheres triethyl citrate - entocort capsules are indicated for the induction of remission in patients with mild to moderate crohn's disease affecting the ileum and/or the ascending colon.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - deferiprone 500mg;   - film coated tablet - 500 mg - active: deferiprone 500mg   excipient: colloidal silicon dioxide hypromellose macrogol 3350 magnesium stearate microcrystalline cellulose titanium dioxide - ferriprox is indicated for the treatment of iron overload in patients with thalassaemia major who are unable to take desferrioxamine therapy or in whom desferrioxamine therapy has proven ineffective.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - deferiprone 100 mg/ml;   - oral solution - 100 mg/ml - active: deferiprone 100 mg/ml   excipient: cherry flavour 33.12676 glycerol hydrochloric acid hyetellose peppermint oil purified water sucralose sunset yellow fcf - ferriprox is indicated for the treatment of iron overload in patients with thalassaemia major who are unable to take desferrioxamine therapy or in whom desferrioxamine therapy has proven ineffective.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - metyrapone 250mg;   - soft gelatin capsule - 250 mg - active: metyrapone 250mg   excipient: acetanisole ethyl hydroxybenzoate as the sodium salt ethyl vanillin gelatin glycerol   ink macrogol 400 macrogol 4000 purified water sodium propyl hydroxybenzoate titanium dioxide - therapeutic applications metopirone can be employed as supplementary therapy in conditions associated with overproduction of glucocorticoids and mineralocorticoids, particularly when causal treatment is not possible. cushing's syndrome, especially when related to adrenal tumours hyperaldosteronism, resistant oedema

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - salcatonin 100 iu/ml;  ;   - solution for injection - 100 iu/ml - active: salcatonin 100 iu/ml     excipient: glacial acetic acid nitrogen sodium acetate trihydrate sodium chloride water for injection - acute bone pain associated with hip arthroplasty osteolysis and osteoporotic vertebral compression fracture.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - cannabidiol 25 mg/ml equivalent to cannabis sativa extract 35 mg-42 mg; tetrahydrocannabinol 27 mg/ml equivalent to cannabis sativa extract 38 mg-44 mg - oral spray - active: cannabidiol 25 mg/ml equivalent to cannabis sativa extract 35 mg-42 mg tetrahydrocannabinol 27 mg/ml equivalent to cannabis sativa extract 38 mg-44 mg excipient: ethanol peppermint oil propylene glycol - sativex is indicated as add-on treatment, for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (ms) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.

Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - formoterol fumarate dihydrate, glycopyrronium, beclometasone dipropionate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - deferiprone 1000mg;   - film coated tablet - 1000 mg - active: deferiprone 1000mg   excipient: crospovidone hyprolose hypromellose macrogol 8000 magnesium stearate methylcellulose titanium dioxide - ferriprox is indicated for the treatment of iron overload in patients with thalassaemia major who are unable to take desferrioxamine therapy or in whom desferrioxamine therapy has proven ineffective.